


Ask a doctor about a prescription for Arizalera
Aripiprazole
Aryzalera contains the active substance aripiprazole and belongs to a group of medicines called antipsychotics. Aryzalera is used to treat adults and adolescents aged 15 and older with a disease characterized by symptoms such as seeing, hearing, and feeling things that do not exist in reality, suspiciousness, false beliefs, chaotic speech and behavior, and emotional numbness. Patients with these symptoms may also experience sadness, guilt, anxiety, or tension.
Aryzalera is used to treat adults and adolescents aged 13 and older whose disease is characterized by symptoms such as excitement, having too much energy, needing much less sleep than usual, very fast speech with racing thoughts, and sometimes severe irritability. In adults, this medicine also prevents the recurrence of these symptoms in patients who have responded to treatment with Aryzalera.
Before starting treatment with Aryzalera, the patient should discuss it with their doctor.
During treatment with aripiprazole, suicidal thoughts and behaviors have been reported. The patient should immediately inform their doctor if they experience thoughts or feelings related to self-harm.
Before starting treatment with Aryzalera, the patient should inform their doctor if they have:
If the patient notices an increase in weight, appearance of unusual movements, drowsiness that interferes with daily activities, difficulty swallowing, or symptoms of an allergic reaction, they should inform their doctor.
If an elderly patient has dementia (loss of memory and other mental abilities), they, their caregiver, or relative should inform the doctor if the patient has ever had a stroke or "mini" stroke.
The patient should immediately inform their doctor if they experience thoughts or feelings related to self-harm. During treatment with aripiprazole, suicidal thoughts and behaviors have been reported.
The patient should immediately inform their doctor if they experience muscle stiffness or stiffness with high fever, excessive sweating, mental disorders, or very fast or irregular heartbeat.
If the patient or their family or caregiver notices that the patient is starting to feel the urge or desire to behave in an unusual way, and cannot resist the impulse, urge, or temptation to engage in activities that may harm them or others, they should tell their doctor. These phenomena are called impulse control disorders and may manifest as behaviors such as compulsive gambling, overeating, or excessive spending, excessive sexual drive, or increased frequency and intensity of thoughts or feelings about sexual topics.
The doctor may consider it appropriate to change the dose or discontinue the medicine.
Aripiprazole may cause drowsiness, decreased blood pressure when standing up, dizziness, and changes in mobility and balance, which can lead to falls. The patient should be careful, especially if they are elderly or weakened.
Aryzalera should not be used in children and adolescents under the age of 13. It is not known if the use of this medicine is safe and effective in these patients.
The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take, including those that are available without a prescription.
Blood pressure-lowering medicines: Aryzalera may enhance the effects of blood pressure-lowering medicines. If the patient is taking blood pressure-lowering medicines, they should inform their doctor.
Taking Aryzalera with certain medicines may require a change in the dose of Aryzalera or other medicines the patient is taking. It is especially important to inform the doctor about the use of the following medicines:
Taking these medicines may increase the risk of side effects or decrease the effect of Aryzalera. If the patient experiences any unusual symptoms while taking these medicines with Aryzalera, they should tell their doctor.
Medicines that increase serotonin levels are usually used to treat depression, generalized anxiety disorder, obsessive-compulsive disorder (OCD), social phobia, and migraine and pain:
Taking these medicines may increase the risk of side effects. If the patient experiences any unusual symptoms while taking these medicines with Aryzalera, they should tell their doctor.
The medicine can be taken with or without food.
The patient should not drink alcohol during treatment with Aryzalera.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a baby, they should consult their doctor before taking this medicine.
In newborns whose mothers took Aryzalera during the last trimester of pregnancy (the last 3 months of pregnancy), the following symptoms may occur: trembling, muscle stiffness, and (or) weakness, drowsiness, agitation, difficulty breathing, and difficulty feeding. If the patient notices any of these symptoms in their child, they should contact their doctor.
If the patient is taking Aryzalera, their doctor will discuss with them whether they should breastfeed, considering the benefits of treatment and the benefits of breastfeeding. The patient should not take the medicine and breastfeed. They should discuss with their doctor the best methods for feeding their child if they are taking this medicine.
During treatment with this medicine, dizziness and vision disturbances (see section 4) may occur.
The patient should take this into account when performing tasks that require full attention, such as driving or operating machinery.
If the patient has previously been diagnosed with intolerance to some sugars, they should contact their doctor before taking this medicine.
This medicine should always be taken as directed by the doctor or pharmacist. If the patient has any doubts, they should consult their doctor or pharmacist.
Aryzalera is available in the following strengths: 5 mg, 10 mg, 15 mg, and 30 mg.
The recommended dose for adults is 15 mg once a day.However, the doctor may prescribe a lower or higher dose, which should not exceed 30 mg once a day.
Aripiprazole treatment can be started with a low dose of aripiprazole oral solution (liquid). The dose may be gradually increased to the recommended dose for adolescents of 10 mg once a day. However, the doctor may prescribe a lower or higher dose, up to a maximum of 30 mg once a day.
If the patient feels that the effect of the medicine is too strong or too weak, they should consult their doctor or pharmacist.
Aryzalera is intended for oral use.
Aryzalera should be taken every day at the same time. It does not matter whether the tablet is taken with food or without food. The tablet should be swallowed whole and washed down with water.
Even if the patient feels an improvement in their condition,they should not change the dose or stop taking Aryzalera without first discussing it with their doctor.
If the patient takes a higher dose than prescribed by their doctor (or if someone else takes some of the medicine not intended for them), they should immediately contact their doctor. If they have difficulty contacting their doctor, they should go to the nearest hospital, taking the medicine packaging with them.
In patients who have taken too much aripiprazole, the following symptoms have occurred:
Other symptoms include:
If the patient experiences any of these symptoms, they should immediately contact their doctor or hospital.
If the patient misses a dose, they should take the missed dose as soon as they remember. They should not take two doses in one day.
The patient should not stop treatment just because they feel better. It is very important to take Aryzalera as directed by the doctor and for the period prescribed by the doctor.
If the patient has any further doubts about taking this medicine, they should consult their doctor or pharmacist.
Like all medicines, Aryzalera can cause side effects, although not everybody gets them.
Uncommon side effects (may affect up to 1 in 100 people):
In elderly patients with dementia taking aripiprazole, more cases of death have been reported. Additionally, cases of stroke or "mini" stroke have been noted.
In adolescents aged 13 and older, side effects occurred with a similar frequency and type as in adults, except for drowsiness, uncontrolled trembling or movements, restlessness, and fatigue, which occurred very frequently (more than 1 in 10 patients), as well as upper abdominal pain, dry mouth, rapid heartbeat, weight gain, increased appetite, muscle tremors, uncontrolled limb movements, and dizziness, especially when standing up from a lying or sitting position, which occurred frequently (more than 1 in 100 patients).
If side effects occur, including any side effects not listed in this leaflet, the patient should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products:
Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
By reporting side effects, more information can be collected on the safety of the medicine.
The medicine should be stored out of sight and reach of children.
The patient should not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month stated.
There are no special precautions for storage.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Light yellow to brownish, round, slightly convex tablets with beveled edges, with possible darker and lighter spots, and engraved with the symbol ",A15" on one side (diameter: 7.5 mm, thickness: 2.5 - 3.7 mm).
Packaging:30, 50, 60, 90 tablets in blisters, in a cardboard box.
For more detailed information, the patient should contact the marketing authorization holder or parallel importer.
Krka, d.d., Novo mesto
Šmarješka cesta 6, 8501, Novo mesto, Slovenia
Krka, d.d., Novo mesto
Šmarješka cesta 6, 8501, Novo mesto, Slovenia
TAD PHARMA GmbH
Heinz-Lohmann-Straße 5, 27472 Cuxhaven
Germany
InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw
InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Marketing authorization number in Romania, the country of export:11819/2019/03
Parallel import authorization number:79/23
[Information about the trademark]
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for Arizalera – subject to medical assessment and local rules.